Śródoperacyjna radioterapia po stereotaktycznej radioterapii ciała i chemioterapii w leczeniu gruczolakoraka trzustki
Badanie bezpieczeństwa śródoperacyjnej radioterapii po stereotaktycznej radioterapii ciała i wielolekowej chemioterapii w leczeniu zlokalizowanego gruczolakoraka trzustki
This study is designed to investigate the safety of intraoperative radiation therapy (IORT) in patients with localized pancreatic cancer undergoing surgical resection after neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT).
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
Standard of care treatment for patients with non-metastatic pancreatic adenocarcinoma (PDAC) includes chemotherapy and Stereotactic Body Radiation Treatment (SBRT) followed by surgical resection of the tumor with or without Intra-Operative Radiation Therapy (IORT).
There is some evidence from other research studies suggesting that adding radiation treatment during the surgical resection may improve local control of the cancer. The use of IORT plus surgical resection can be used to treat pancreatic cancer and is done on a case by case basis at Johns Hopkins.
The department of Radiation Oncology has developed a program using a High Dose Rate-IORT (HDR-IORT). The HDR-IORT makes it possible to deliver concentrated radiation dose at the surface of the tumor.
Our team has shown in previous studies that the majority of cancer cells that remain after treatment are located around the area of the pancreas called the "Triangle Volume" (TV). This region contains blood vessels, lymphatic vessels, and nerves, and is at high risk of containing cancer cells. This region is difficult to treat with SBRT alone because of being close to normal, healthy organs. Therefore, this study involves using IORT to treat the TV to a therapeutic radiation dose.
The part of the treatment that is considered research is:
- Giving one dose of 15 Gy during the surgery using IORT to deliver radiation, and
- Targeting the larger area around the pancreas called the TV
The goal of this study is to determine safety of this added treatment which will be assessed at 3 months after the surgery is completed.
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 1
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Maryland
-
Baltimore, Maryland, Stany Zjednoczone, 21205
- Johns Hopkins Hospital
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Age > 18 years old
- Resectable/BRPC/LAPC as defined by NCCN guidelines (Figure 1) as follows confirmed via CT, EUS, or other imaging modalities.
- ECOG performance status 0-2
- Subject or authorized representative, has been informed of the nature of the study and has provided written informed consent, approved by the appropriate Institutional Review Board (IRB) of the respective clinical site.
- Candidate for SBRT at JHU
- Upfront treatment with multi-agent chemotherapy
- Candidate for surgical exploration at JHU
Exclusion Criteria:
- Previous thoracic/abdominal radiation therapy
- Unable to receive SBRT at JHU
- Duodenal invasion detected on imaging which would exclude candidacy for SBRT
- Tumor located in pancreatic body or tail
- Unable to undergo Whipple procedure
- Evidence of disease not localized to the pancreas
- Any arterial reconstruction during surgery
- Currently enrolled in another investigational drug or device trial that clinically interferes with this study
- Unable to comply with study requirements or follow-up schedule
- Women of child bearing potential or sexually active fertile men with partners who are women of child bearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Nie dotyczy
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Inny: Intra Operative Radiation Therapy (IORT) Group
The IORT group is the single arm of this study. Enrolled patients who undergo standard of care treatment will also receive a study treatment of High Dose Rate (HDR) Intra Operative Radiation Therapy. |
After the patient receives standard of care treatment, they will receive a single dose of radiation (15 Gy) at the time the tumor is surgically removed. Surgeons will then place clips along the blood vessels around the surgical area. These clips will be used to confirm (after surgery) that the expected dose of radiation was received during surgery. |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Acute post-operative toxicity of targeted IORT
Ramy czasowe: 3 months
|
To evaluate acute post-operative toxicity of IORT targeted to the TV in patients with non-metastatic PDAC undergoing surgical resection after neoadjuvant multi-agent chemotherapy and SBRT. |
3 months
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Late post-operative toxicity of targeted IORT
Ramy czasowe: 6 months
|
To evaluate late toxicity of IORT targeted to the TV in patients with non-metastatic PDAC undergoing surgical resection after neoadjuvant multi-agent chemotherapy and SBRT. To evaluate late toxicity (>90 days) of IORT targeted to the TV in patients with non-metastatic PDAC undergoing surgical resection after neoadjuvant multi-agent chemotherapy and SBRT. |
6 months
|
|
Late post-operative toxicity of targeted IORT
Ramy czasowe: 12 months
|
To evaluate late toxicity of IORT targeted to the TV in patients with non-metastatic PDAC undergoing surgical resection after neoadjuvant multi-agent chemotherapy and SBRT. To evaluate late toxicity (>90 days) of IORT targeted to the TV in patients with non-metastatic PDAC undergoing surgical resection after neoadjuvant multi-agent chemotherapy and SBRT. |
12 months
|
|
Late post-operative toxicity of targeted IORT
Ramy czasowe: 24 months
|
To evaluate late toxicity of IORT targeted to the TV in patients with non-metastatic PDAC undergoing surgical resection after neoadjuvant multi-agent chemotherapy and SBRT. To evaluate late toxicity (>90 days) of IORT targeted to the TV in patients with non-metastatic PDAC undergoing surgical resection after neoadjuvant multi-agent chemotherapy and SBRT. |
24 months
|
|
Late post-operative toxicity of targeted IORT
Ramy czasowe: 36 months
|
To evaluate late toxicity of IORT targeted to the TV in patients with non-metastatic PDAC undergoing surgical resection after neoadjuvant multi-agent chemotherapy and SBRT. To evaluate late toxicity (>90 days) of IORT targeted to the TV in patients with non-metastatic PDAC undergoing surgical resection after neoadjuvant multi-agent chemotherapy and SBRT. |
36 months
|
|
Median local-progression free survival (LPFS) from IORT
Ramy czasowe: 6 months
|
To determine the median local-progression free survival (LPFS) from time of IORT. |
6 months
|
|
Median local-progression free survival (LPFS) from IORT
Ramy czasowe: 12 months
|
To determine the median local-progression free survival (LPFS) from time of IORT. |
12 months
|
|
Median local-progression free survival (LPFS) from IORT
Ramy czasowe: 24 months
|
To determine the median local-progression free survival (LPFS) from time of IORT. |
24 months
|
|
Median local-progression free survival (LPFS) from IORT
Ramy czasowe: 36 months
|
To determine the median local-progression free survival (LPFS) from time of IORT. |
36 months
|
|
Median overall survival (OS) from IORT
Ramy czasowe: 6 months
|
To determine the median overall survival (OS) from time of IORT. |
6 months
|
|
Median overall survival (OS) from IORT
Ramy czasowe: 12 months
|
To determine the median overall survival (OS) from time of IORT. |
12 months
|
|
Median overall survival (OS) from IORT
Ramy czasowe: 24 months
|
To determine the median overall survival (OS) from time of IORT. |
24 months
|
|
Median overall survival (OS) from IORT
Ramy czasowe: 36 months
|
To determine the median overall survival (OS) from time of IORT. |
36 months
|
|
Median progression free survival (PFS) from IORT
Ramy czasowe: 6 months
|
To determine the median progression free survival (PFS) from time of IORT |
6 months
|
|
Median progression free survival (PFS) from IORT
Ramy czasowe: 12 months
|
To determine the median progression free survival (PFS) from time of IORT |
12 months
|
|
Median progression free survival (PFS) from IORT
Ramy czasowe: 24 months
|
To determine the median progression free survival (PFS) from time of IORT |
24 months
|
|
Median progression free survival (PFS) from IORT
Ramy czasowe: 36 months
|
To determine the median progression free survival (PFS) from time of IORT |
36 months
|
Współpracownicy i badacze
Śledczy
- Główny śledczy: Amol Narang, MD, JHU, School of Medicine, SKCCC
Publikacje i pomocne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- J21105
- IRB00294801 (Inny identyfikator: Johns Hopkins Medicine)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
produkt wyprodukowany i wyeksportowany z USA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .